Irene Pichler
University of Lübeck
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Irene Pichler.
Nature Communications | 2015
Beben Benyamin; Tonu Esko; Janina S. Ried; Aparna Radhakrishnan; Sita H. Vermeulen; Michela Traglia; Martin Goegele; Denise Anderson; Linda Broer; Clara Podmore; Jian'an Luan; Zoltán Kutalik; Serena Sanna; Peter van der Meer; Toshiko Tanaka; Fudi Wang; Harm-Jan Westra; Lude Franke; Evelin Mihailov; Lili Milani; Jonas Haelldin; Juliane Winkelmann; Thomas Meitinger; Joachim Thiery; Annette Peters; Melanie Waldenberger; Augusto Rendon; Jennifer Jolley; Jennifer Sambrook; Lambertus A. Kiemeney
Corrigendum: Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis
Nature Genetics | 2009
Yurii S. Aulchenko; Samuli Ripatti; Ida Lindqvist; Dorret I. Boomsma; Iris M. Heid; Peter P. Pramstaller; Brenda W.J.H. Penninx; A. Cecile J. W. Janssens; James F. Wilson; Tim D. Spector; Nicholas G. Martin; Nancy L. Pedersen; Kirsten Ohm Kyvik; Jaakko Kaprio; Albert Hofman; Nelson B. Freimer; Marjo-Riitta Järvelin; Ulf Gyllensten; Harry Campbell; Igor Rudan; Åsa Johansson; Fabio Marroni; Caroline Hayward; Veronique Vitart; Inger Jonasson; Cristian Pattaro; Alan F. Wright; Nicholas D. Hastie; Irene Pichler; Andrew A. Hicks
Recent genome-wide association (GWA) studies of lipids have been conducted in samples ascertained for other phenotypes, particularly diabetes. Here we report the first GWA analysis of loci affecting total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides sampled randomly from 16 population-based cohorts and genotyped using mainly the Illumina HumanHap300-Duo platform. Our study included a total of 17,797–22,562 persons, aged 18–104 years and from geographic regions spanning from the Nordic countries to Southern Europe. We established 22 loci associated with serum lipid levels at a genome-wide significance level (P < 5 × 10−8), including 16 loci that were identified by previous GWA studies. The six newly identified loci in our cohort samples are ABCG5 (TC, P = 1.5 × 10−11; LDL, P = 2.6 × 10−10), TMEM57 (TC, P = 5.4 × 10−10), CTCF-PRMT8 region (HDL, P = 8.3 × 10−16), DNAH11 (LDL, P = 6.1 × 10−9), FADS3-FADS2 (TC, P = 1.5 × 10−10; LDL, P = 4.4 × 10−13) and MADD-FOLH1 region (HDL, P = 6 × 10−11). For three loci, effect sizes differed significantly by sex. Genetic risk scores based on lipid loci explain up to 4.8% of variation in lipids and were also associated with increased intima media thickness (P = 0.001) and coronary heart disease incidence (P = 0.04). The genetic risk score improves the screening of high-risk groups of dyslipidemia over classical risk factors.
PLOS Genetics | 2009
Andrew A. Hicks; Peter P. Pramstaller; Åsa Johansson; Veronique Vitart; Igor Rudan; Peter Ugocsai; Yurii S. Aulchenko; Christopher S. Franklin; Gerhard Liebisch; Jeanette Erdmann; Inger Jonasson; Irina V. Zorkoltseva; Cristian Pattaro; Caroline Hayward; Aaron Isaacs; Christian Hengstenberg; Susan Campbell; Carsten Gnewuch; A. CecileJ.W. Janssens; Anatoly V. Kirichenko; Inke R. König; Fabio Marroni; Ozren Polašek; Ayse Demirkan; Ivana Kolcic; Christine Schwienbacher; Wilmar Igl; Zrinka Biloglav; Jacqueline C. M. Witteman; Irene Pichler
Sphingolipids have essential roles as structural components of cell membranes and in cell signalling, and disruption of their metabolism causes several diseases, with diverse neurological, psychiatric, and metabolic consequences. Increasingly, variants within a few of the genes that encode enzymes involved in sphingolipid metabolism are being associated with complex disease phenotypes. Direct experimental evidence supports a role of specific sphingolipid species in several common complex chronic disease processes including atherosclerotic plaque formation, myocardial infarction (MI), cardiomyopathy, pancreatic β-cell failure, insulin resistance, and type 2 diabetes mellitus. Therefore, sphingolipids represent novel and important intermediate phenotypes for genetic analysis, yet little is known about the major genetic variants that influence their circulating levels in the general population. We performed a genome-wide association study (GWAS) between 318,237 single-nucleotide polymorphisms (SNPs) and levels of circulating sphingomyelin (SM), dihydrosphingomyelin (Dih-SM), ceramide (Cer), and glucosylceramide (GluCer) single lipid species (33 traits); and 43 matched metabolite ratios measured in 4,400 subjects from five diverse European populations. Associated variants (32) in five genomic regions were identified with genome-wide significant corrected p-values ranging down to 9.08×10−66. The strongest associations were observed in or near 7 genes functionally involved in ceramide biosynthesis and trafficking: SPTLC3, LASS4, SGPP1, ATP10D, and FADS1–3. Variants in 3 loci (ATP10D, FADS3, and SPTLC3) associate with MI in a series of three German MI studies. An additional 70 variants across 23 candidate genes involved in sphingolipid-metabolizing pathways also demonstrate association (p = 10−4 or less). Circulating concentrations of several key components in sphingolipid metabolism are thus under strong genetic control, and variants in these loci can be tested for a role in the development of common cardiovascular, metabolic, neurological, and psychiatric diseases.
Atherosclerosis | 2010
Iris M. Heid; Peter Henneman; Andrew A. Hicks; Stefan Coassin; Thomas W. Winkler; Yurii S. Aulchenko; Christian Fuchsberger; Kijoung Song; Marie-France Hivert; Dawn M. Waterworth; Nicholas J. Timpson; J. Brent Richards; John Perry; Toshiko Tanaka; Najaf Amin; Barbara Kollerits; Irene Pichler; Ben A. Oostra; Barbara Thorand; Rune R. Frants; Thomas Illig; Josée Dupuis; Beate Glaser; Tim D. Spector; Jack M. Guralnik; Josephine M. Egan; Jose C. Florez; David Evans; Nicole Soranzo; Stefania Bandinelli
OBJECTIVE Plasma adiponectin is strongly associated with various components of metabolic syndrome, type 2 diabetes and cardiovascular outcomes. Concentrations are highly heritable and differ between men and women. We therefore aimed to investigate the genetics of plasma adiponectin in men and women. METHODS We combined genome-wide association scans of three population-based studies including 4659 persons. For the replication stage in 13795 subjects, we selected the 20 top signals of the combined analysis, as well as the 10 top signals with p-values less than 1.0 x 10(-4) for each the men- and the women-specific analyses. We further selected 73 SNPs that were consistently associated with metabolic syndrome parameters in previous genome-wide association studies to check for their association with plasma adiponectin. RESULTS The ADIPOQ locus showed genome-wide significant p-values in the combined (p=4.3 x 10(-24)) as well as in both women- and men-specific analyses (p=8.7 x 10(-17) and p=2.5 x 10(-11), respectively). None of the other 39 top signal SNPs showed evidence for association in the replication analysis. None of 73 SNPs from metabolic syndrome loci exhibited association with plasma adiponectin (p>0.01). CONCLUSIONS We demonstrated the ADIPOQ gene as the only major gene for plasma adiponectin, which explains 6.7% of the phenotypic variance. We further found that neither this gene nor any of the metabolic syndrome loci explained the sex differences observed for plasma adiponectin. Larger studies are needed to identify more moderate genetic determinants of plasma adiponectin.
PLOS Genetics | 2012
Ayse Demirkan; Cornelia M. van Duijn; Peter Ugocsai; Aaron Isaacs; Peter P. Pramstaller; Gerhard Liebisch; James F. Wilson; Åsa Johansson; Igor Rudan; Yurii S. Aulchenko; Anatoly V. Kirichenko; A. Cecile J. W. Janssens; Ritsert C. Jansen; Carsten Gnewuch; Francisco S. Domingues; Cristian Pattaro; Sarah H. Wild; Inger Jonasson; Ozren Polasek; Irina V. Zorkoltseva; Albert Hofman; Lennart C. Karssen; Maksim Struchalin; James A B Floyd; Wilmar Igl; Zrinka Biloglav; Linda Broer; Arne Pfeufer; Irene Pichler; Susan Campbell
Phospho- and sphingolipids are crucial cellular and intracellular compounds. These lipids are required for active transport, a number of enzymatic processes, membrane formation, and cell signalling. Disruption of their metabolism leads to several diseases, with diverse neurological, psychiatric, and metabolic consequences. A large number of phospholipid and sphingolipid species can be detected and measured in human plasma. We conducted a meta-analysis of five European family-based genome-wide association studies (N = 4034) on plasma levels of 24 sphingomyelins (SPM), 9 ceramides (CER), 57 phosphatidylcholines (PC), 20 lysophosphatidylcholines (LPC), 27 phosphatidylethanolamines (PE), and 16 PE-based plasmalogens (PLPE), as well as their proportions in each major class. This effort yielded 25 genome-wide significant loci for phospholipids (smallest P-value = 9.88×10−204) and 10 loci for sphingolipids (smallest P-value = 3.10×10−57). After a correction for multiple comparisons (P-value<2.2×10−9), we observed four novel loci significantly associated with phospholipids (PAQR9, AGPAT1, PKD2L1, PDXDC1) and two with sphingolipids (PLD2 and APOE) explaining up to 3.1% of the variance. Further analysis of the top findings with respect to within class molar proportions uncovered three additional loci for phospholipids (PNLIPRP2, PCDH20, and ABDH3) suggesting their involvement in either fatty acid elongation/saturation processes or fatty acid specific turnover mechanisms. Among those, 14 loci (KCNH7, AGPAT1, PNLIPRP2, SYT9, FADS1-2-3, DLG2, APOA1, ELOVL2, CDK17, LIPC, PDXDC1, PLD2, LASS4, and APOE) mapped into the glycerophospholipid and 12 loci (ILKAP, ITGA9, AGPAT1, FADS1-2-3, APOA1, PCDH20, LIPC, PDXDC1, SGPP1, APOE, LASS4, and PLD2) to the sphingolipid pathways. In large meta-analyses, associations between FADS1-2-3 and carotid intima media thickness, AGPAT1 and type 2 diabetes, and APOA1 and coronary artery disease were observed. In conclusion, our study identified nine novel phospho- and sphingolipid loci, substantially increasing our knowledge of the genetic basis for these traits.
American Journal of Human Genetics | 2006
Irene Pichler; Fabio Marroni; Claudia B. Volpato; James F. Gusella; Christine Klein; Giorgio Casari; Alessandro De Grandi; Peter P. Pramstaller
Restless legs syndrome (RLS) is a common neurological condition with three loci (12q, 14q, and 9p) described so far, although none of these genes has yet been identified. We report a genomewide linkage scan of patients with RLS (n=37) assessed in a population isolate (n=530) of South Tyrol (Italy). Using both nonparametric and parametric analyses, we initially obtained suggestive evidence of a novel locus on chromosome 2q, with nominal evidence of linkage on chromosomes 5p and 17p. Follow-up genotyping yielded significant evidence of linkage (nonparametric LOD score 5.5, P<or=.0000033; heterogeneity LOD score 5.1; alpha =1.0) on chromosome 2q. Three families (S01, S05, and S016) were shown to descend from a common founder couple. A disease haplotype shared between family S01 and family S05 defines a candidate region of 8.2 cM; in addition, the single affected individual in family S016 shares three linked alleles at neighboring markers, which suggests a reduced candidate interval of only 1.6 cM. Two-point linkage analysis in this 10-generation pedigree provided significant evidence of a novel RLS locus in this region (LOD score 4.1). These findings reemphasize the genetic heterogeneity of the disorder and strongly support the identification of a novel locus for RLS on chromosome 2q.
Biological Psychiatry | 2010
Karla V. Allebrandt; Maris Teder-Laving; Mahmut Akyol; Irene Pichler; Bertram Müller-Myhsok; Peter P. Pramstaller; Martha Merrow; Thomas Meitinger; Andreas Metspalu; Till Roenneberg
BACKGROUND Sleep is an active and complex behavior, yet it has two straightforward properties-timing and duration. Clock genes are associated with dysfunctional timing of sleep, mood, and obesity disorders, which are commonly associated with sleep duration. METHODS Sleep duration was assessed in Central Europe, Estonia, and South Tyrol (n approximately 77,000) with the Munich ChronoType Questionnaire. It showed a Gaussian distribution in all investigated populations after averaging over a standard workweek and normalization according to age and gender. A follow-up, two-stage design, linkage disequilibrium-based association study was conducted with subjects from South Tyrol (discovery sample; n = 283) and with short (< 7 hours) and long (> 8.5 hours) sleepers from Estonia (confirmation sample; n = 1011). One hundred ninety-four single nucleotide polymorphism markers covering 19 candidate clock genes were genotyped in the discovery sample, and two of the best association signals (analyzed by a linear regression model) were investigated in the confirmation sample. RESULTS Single and multi-marker associations were found within a CLOCK gene intronic region (rs12649507 and rs11932595). In a meta-analysis between South Tyrol and Estonia association signals, rs12649507 (p = .0087) remained significant. Significance persisted only for the multiple-marker association signal of the rs12649507/rs11932595 haplotype GGAA with long sleep (p = .0015). CONCLUSIONS We report an association between variants of the human CLOCK gene and sleep duration in two independent populations. This adds another putative function for CLOCK besides its possible involvement in circadian timing, depression, obesity, and personality.
Human Molecular Genetics | 2009
Åsa Johansson; Fabio Marroni; Caroline Hayward; Christopher S. Franklin; Anatoly V. Kirichenko; Inger Jonasson; Andrew A. Hicks; Veronique Vitart; Aaron Isaacs; Tatiana I. Axenovich; Susan Campbell; Malcolm G. Dunlop; Jamie Floyd; Nicholas D. Hastie; Albert Hofman; Sara Knott; Ivana Kolcic; Irene Pichler; Ozren Polašek; Fernando Rivadeneira; Albert Tenesa; André G. Uitterlinden; Sarah H. Wild; Irina V. Zorkoltseva; Thomas Meitinger; James F. Wilson; Igor Rudan; Harry Campbell; Cristian Pattaro; Peter P. Pramstaller
Genes for height have gained interest for decades, but only recently have candidate genes started to be identified. We have performed linkage analysis and genome-wide association for height in approximately 4000 individuals from five European populations. A total of five chromosomal regions showed suggestive linkage and in one of these regions, two SNPs (rs849140 and rs1635852) were associated with height (nominal P = 7.0 x 10(-8) and P = 9.6 x 10(-7), respectively). In total, five SNPs across the genome showed an association with height that reached the threshold of genome-wide significance (nominal P < 1.6 x 10(-7)). The association with height was replicated for two SNPs (rs1635852 and rs849140) using three independent studies (n = 31 077, n=1268 and n = 5746) with overall meta P-values of 9.4 x 10(-10) and 5.3 x 10(-8). These SNPs are located in the JAZF1 gene, which has recently been associated with type II diabetes, prostate and endometrial cancer. JAZF1 is a transcriptional repressor of NR2C2, which results in low IGF1 serum concentrations, perinatal and early postnatal hypoglycemia and growth retardation when knocked out in mice. Both the linkage and association analyses independently identified the JAZF1 region affecting human height. We have demonstrated, through replication in additional independent populations, the consistency of the effect of the JAZF1 SNPs on height. Since this gene also has a key function in the metabolism of growth, JAZF1 represents one of the strongest candidates influencing human height identified so far.
Kidney International | 2009
Cristian Pattaro; Yurii S. Aulchenko; Aaron Isaacs; Veronique Vitart; Caroline Hayward; Christopher S. Franklin; Ozren Polašek; Ivana Kolcic; Zrinka Biloglav; Susan Campbell; Nicholas D. Hastie; Gordan Lauc; Thomas Meitinger; Benjamin A. Oostra; Ulf Gyllensten; James F. Wilson; Irene Pichler; Andrew A. Hicks; Harry Campbell; Alan F. Wright; Igor Rudan; Cornelia van Duijn; Peter Riegler; Fabio Marroni; Peter P. Pramstaller
There is increasing evidence for a role of genetic predisposition in the etiology of kidney disease, but linkage scans have been poorly replicated. Here we performed a genome-wide linkage analysis of serum creatinine on 2859 individuals from isolated villages in South Tyrol (Italy), Rucphen (The Netherlands) and Vis Island (Croatia), populations that have been stable and permanently resident in their region. Linkage of serum creatinine levels to loci on chromosomes 7p14, 9p21, 11p15, 15q15-21, 16p13, and 18p11 was successfully replicated in at least one discovery population or in the pooled analysis. A novel locus was found on chromosome 10p11. Linkage to chromosome 22q13, independent of diabetes and hypertension, was detected over a region containing the non-muscle myosin heavy chain type II isoform A (MYH9) gene (LOD score=3.52). In non-diabetic individuals, serum creatinine was associated with this gene in two of the three populations and in meta-analysis (SNP rs11089788, P-value=0.0089). In populations sharing a homogeneous environment and genetic background, heritability of serum creatinine was higher than in outbred populations, with consequent detection of a larger number of loci than reported before. Our finding of a replicated association of serum creatinine with the MYH9 gene, recently linked to pathological renal conditions in African Americans, suggests that this gene may also influence kidney function in healthy Europeans.
BMC Medical Genetics | 2007
Cristian Pattaro; Fabio Marroni; Alice Riegler; Deborah Mascalzoni; Irene Pichler; Claudia B. Volpato; Umberta Dal Cero; Alessandro De Grandi; Clemens Egger; Agatha Eisendle; Christian Fuchsberger; Martin Gögele; Sara Pedrotti; Gerd K. Pinggera; Stefan A. Stefanov; Florian D. Vogl; Christian J. Wiedermann; Thomas Meitinger; Peter P. Pramstaller
BackgroundThere is increasing evidence of the important role that small, isolated populations could play in finding genes involved in the etiology of diseases. For historical and political reasons, South Tyrol, the northern most Italian region, includes several villages of small dimensions which remained isolated over the centuries.MethodsThe MICROS study is a population-based survey on three small, isolated villages, characterized by: old settlement; small number of founders; high endogamy rates; slow/null population expansion. During the stage-1 (2002/03) genealogical data, screening questionnaires, clinical measurements, blood and urine samples, and DNA were collected for 1175 adult volunteers. Stage-2, concerning trait diagnoses, linkage analysis and association studies, is ongoing. The selection of the traits is being driven by expert clinicians. Preliminary, descriptive statistics were obtained. Power simulations for finding linkage on a quantitative trait locus (QTL) were undertaken.ResultsStarting from participants, genealogies were reconstructed for 50,037 subjects, going back to the early 1600s. Within the last five generations, subjects were clustered in one pedigree of 7049 subjects plus 178 smaller pedigrees (3 to 85 subjects each). A significant probability of familial clustering was assessed for many traits, especially among the cardiovascular, neurological and respiratory traits. Simulations showed that the MICROS pedigree has a substantial power to detect a LOD score ≥ 3 when the QTL specific heritability is ≥ 20%.ConclusionThe MICROS study is an extensive, ongoing, two-stage survey aimed at characterizing the genetic epidemiology of Mendelian and complex diseases. Our approach, involving different scientific disciplines, is an advantageous strategy to define and to study population isolates. The isolation of the Alpine populations, together with the extensive data collected so far, make the MICROS study a powerful resource for the study of diseases in many fields of medicine. Recent successes and simulation studies give us confidence that our pedigrees can be valuable both in finding new candidates loci and to confirm existing candidate genes.